Nimbus

View All

recent-pharma-news-updates-cyclerion-nimbus-dyno-rayzebio
Cyclerion’s olinciguat flunks sickle cell test; Nimbus nets $60M; Dyno-Roche’s gene therapy pact; RayzeBio debuts with $ 45M to target tumors

Cyclerion flunks sickle cell test, prompting pivot to CNS disease Cyclerion Therapeutics has terminated the development of olinciguat in sickle cell disease after getting a look at data from a phase 2 trial. The setback caused Cyclerion to switch its focus to IW-6463 and to treat central nervous system diseases....

Find More